April 3, 2014 12:30 UTC

VeriTeQ Corporation to Sponsor and Present at 11th International Committee for Quality Assurance, Medical Technologies and Devices in Plastic Surgery Congress and Consensus Conference

VeriTeQ Symposium to Educate Leading Plastic Surgeons on its Q Inside Safety Technology for Breast Implants and Other Implanted Medical Devices

DELRAY BEACH, Fla.--(BUSINESS WIRE)-- VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it is sponsoring and presenting at the 11th IQUAM (the International Committee for Quality Assurance, Medical Technologies and Devices in Plastic Surgery) Congress and Consensus Conference April 10-13, 2014, in Budapest, Hungary. VeriTeQ’s President, Randolph Geissler, will host a symposium to educate plastic surgeons on the Company’s Q Inside Safety Technology, currently being used in breast implants.

VeriTeQ’s FDA cleared Q Inside Safety Technology acts as an electronic serial number in breast implants and other implantable and reusable medical devices to give physicians and patients access to a secure online database to retrieve device-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. Q Inside Safety Technology also provides an extra level of protection to the patient in the event of a recall or other safety event.

IQUAM, established in 1992, is a professional data-generating medical and scientific organization dedicated to the assurance of the safe use of medical devices, technologies and procedures in plastic surgery, as well as to ensuring patient safety.

“We look forward to this opportunity to educate the global plastic surgery community on our Q Inside Safety Technology, which is now being used in breast implants,” said Scott R. Silverman, VeriTeQ’s Chairman and CEO. “Following two broad recalls of breast implants in the EU, we believe patients and surgeons alike will demand accurate device verification of implants and the added level of security offered by our Q Inside Safety Technology.”


IQUAM is a vivid and active Society within the structure of IPRAS (the International Confederation for Plastic and Reconstructive & Aesthetic Surgery), with a unique task to provide guidance and opinions on the role and safety of materials and techniques employed in this specialty. The most important product of the biennially organized world conference with delegates from all Societies of IPRAS (over 100), is the "Position Statement," which is a public statement circulated among all interested parties e.g. Scientific Societies, Industry, Government officials, Individual Plastic Surgeons, Researchers and others.

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Statements in this press release about our future expectations, including the likelihood that patients and surgeons alike will demand accurate device verification of implants and the added level of security offered by Q Inside Safety Technology, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


Allison Tomek, 561-846-7003
RedChip Companies
Brendan Hopkins, 1-800-RED-CHIP (733-2447) Ext 134

Source: VeriTeQ Corporation